Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease
Launched by TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. · Sep 13, 2005
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Patients who completed evaluations of week 52 of the TVP 1012/232 protocol, where continued rasagiline therapy is warranted, in the opinion of the principal investigator
- Exclusion Criteria:
- • • Patients having suffered adverse effects that were probably drug-related in the TVP-1012/232 study
About Teva Branded Pharmaceutical Products R&D, Inc.
Teva Branded Pharmaceutical Products R&D, Inc. is a leading global pharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a strong emphasis on delivering high-quality medicines across various therapeutic areas, Teva leverages its extensive expertise in drug development and manufacturing to advance healthcare outcomes. The company's commitment to scientific excellence and patient-centric approaches drives its clinical trial initiatives, focusing on addressing unmet medical needs and improving the quality of life for patients worldwide. Through robust partnerships and a comprehensive portfolio, Teva continues to play a pivotal role in the pharmaceutical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Phyllis Salzman, Ph.D.
Study Director
Teva Neuroscience, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials